NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Dahabreh IJ, Moorthy D, Lamont JL, et al. Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Sep. (Comparative Effectiveness Reviews, No. 125.)
Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment [Internet].
Show detailsThe Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.
Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm
AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input.
We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to vog.shh.qrha@cpe.
- Richard G. Kronick, Ph.D.DirectorAgency for Healthcare Research and Quality
- Stephanie Chang, M.D., M.P.H.DirectorEvidence-based Practice ProgramCenter for Outcomes and EvidenceAgency for Healthcare Research and Quality
- Jean Slutsky, P.A., M.S.P.H.Director, Center for Outcomes and EvidenceAgency for Healthcare Research and Quality
- Elisabeth Kato, M.D., M.R.P.Task Order OfficerCenter for Outcomes and EvidenceAgency for Healthcare Research and Quality
- Preface - Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antipl...Preface - Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment
- Detailed Assessment of the Strength of Evidence - Testing of CYP2C19 Variants an...Detailed Assessment of the Strength of Evidence - Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment
- MRSA Full-Text Screening Form - Screening for Methicillin-Resistant Staphylococc...MRSA Full-Text Screening Form - Screening for Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Risk-of-Bias Tables - Otitis Media With Effusion: Comparative Effectiveness of T...Risk-of-Bias Tables - Otitis Media With Effusion: Comparative Effectiveness of Treatments
- Appendix Tables for Key Question 1 - Testing of CYP2C19 Variants and Platelet Re...Appendix Tables for Key Question 1 - Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment
Your browsing activity is empty.
Activity recording is turned off.
See more...